BioNTech SE Profit Margin

The latest profit margin for BNTX is -44.95% as of March 2026. That compares with -28.03% in the prior-year period — down 60.4% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside BioNTech SE's historical trend and sector peers before judging valuation or financial health.

Over the past year, BNTX's profit margin moved from -28.03% to -44.95% — a 60.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioNTech SE's valuation or profitability profile.

Against Healthcare companies, BNTX currently prints -44.95% for profit margin, while the sector average sits near 15.58%. That is roughly 388.5% below the sector mean. Large gaps often invite a closer look at BioNTech SE's growth, margins, and balance sheet.

Profit Margin shows how effectively BioNTech SE converts resources into returns. At -44.95%, BNTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -28.03% in the prior-year period — down 60.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BNTX's profit margin (-44.95%), review year-over-year change from -28.03%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.